DNA X INC (SONM) Fundamental Analysis & Valuation

NASDAQ:SONM • US83548F4081

Current stock price

4.43 USD
+0.34 (+8.31%)
Last:

This SONM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SONM Profitability Analysis

1.1 Basic Checks

  • In the past year SONM has reported negative net income.
  • In the past year SONM has reported a negative cash flow from operations.
  • SONM had negative earnings in each of the past 5 years.
  • In the past 5 years SONM always reported negative operating cash flow.
SONM Yearly Net Income VS EBIT VS OCF VS FCFSONM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of SONM (-83.01%) is worse than 83.78% of its industry peers.
Industry RankSector Rank
ROA -83.01%
ROE N/A
ROIC N/A
ROA(3y)-37.03%
ROA(5y)-52.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SONM Yearly ROA, ROE, ROICSONM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • SONM has a worse Gross Margin (18.33%) than 64.86% of its industry peers.
  • SONM's Gross Margin has declined in the last couple of years.
  • SONM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.23%
GM growth 5Y-10.52%
SONM Yearly Profit, Operating, Gross MarginsSONM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SONM Health Analysis

2.1 Basic Checks

  • SONM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SONM has been increased compared to 1 year ago.
  • SONM has more shares outstanding than it did 5 years ago.
  • SONM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SONM Yearly Shares OutstandingSONM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
SONM Yearly Total Debt VS Total AssetsSONM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • SONM has an Altman-Z score of -11.56. This is a bad value and indicates that SONM is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -11.56, SONM is not doing good in the industry: 81.08% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.56
ROIC/WACCN/A
WACC8.92%
SONM Yearly LT Debt VS Equity VS FCFSONM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.78 indicates that SONM may have some problems paying its short term obligations.
  • SONM's Current ratio of 0.78 is on the low side compared to the rest of the industry. SONM is outperformed by 78.38% of its industry peers.
  • SONM has a Quick Ratio of 0.78. This is a bad value and indicates that SONM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.50, SONM is doing worse than 75.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.5
SONM Yearly Current Assets VS Current LiabilitesSONM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SONM Growth Analysis

3.1 Past

  • SONM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -84.15%.
  • SONM shows a small growth in Revenue. In the last year, the Revenue has grown by 4.17%.
  • Measured over the past years, SONM shows a very negative growth in Revenue. The Revenue has been decreasing by -12.90% on average per year.
EPS 1Y (TTM)-84.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.22%
Revenue 1Y (TTM)4.17%
Revenue growth 3Y2.21%
Revenue growth 5Y-12.9%
Sales Q2Q%7.94%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y126.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year107.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SONM Yearly Revenue VS EstimatesSONM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SONM Yearly EPS VS EstimatesSONM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2023 2024 2025 0 -500 -1K -1.5K -2K

More info and screens

Find the best growth stocksShow best growing peers

4

4. SONM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SONM. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 5.17, which indicates a rather cheap valuation of SONM.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SONM indicates a rather cheap valuation: SONM is cheaper than 97.30% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.84. SONM is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 5.17
SONM Price Earnings VS Forward Price EarningsSONM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SONM Per share dataSONM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40 -60 -80

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SONM Dividend Analysis

5.1 Amount

  • SONM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SONM Fundamentals: All Metrics, Ratios and Statistics

DNA X INC

NASDAQ:SONM (3/13/2026, 8:00:02 PM)

4.43

+0.34 (+8.31%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)11-12
Earnings (Next)03-30
Inst Owners5.68%
Inst Owner Change-86.47%
Ins Owners17.77%
Ins Owner Change0.36%
Market Cap6.60M
Revenue(TTM)59.11M
Net Income(TTM)-33.38M
Analysts82.86
Price TargetN/A
Short Float %3.03%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-58.05%
Min Revenue beat(2)-62.39%
Max Revenue beat(2)-53.71%
Revenue beat(4)0
Avg Revenue beat(4)-44.12%
Min Revenue beat(4)-62.39%
Max Revenue beat(4)-24.88%
Revenue beat(8)1
Avg Revenue beat(8)-29.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.17
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-96.99
EYN/A
EPS(NY)0.86
Fwd EY19.34%
FCF(TTM)-17.48
FCFYN/A
OCF(TTM)-17.47
OCFYN/A
SpS39.67
BVpS-0.47
TBVpS-6.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.33%
FCFM N/A
ROA(3y)-37.03%
ROA(5y)-52.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.23%
GM growth 5Y-10.52%
F-Score2
Asset Turnover1.47
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.5
Altman-Z -11.56
F-Score2
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)2.69%
Cap/Depr(5y)2.16%
Cap/Sales(3y)0.14%
Cap/Sales(5y)0.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-84.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.22%
EPS Next Y126.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.17%
Revenue growth 3Y2.21%
Revenue growth 5Y-12.9%
Sales Q2Q%7.94%
Revenue Next Year107.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-228.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year156.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-338.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-339.71%
OCF growth 3YN/A
OCF growth 5YN/A

DNA X INC / SONM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DNA X INC (SONM) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SONM.


Can you provide the valuation status for DNA X INC?

ChartMill assigns a valuation rating of 4 / 10 to DNA X INC (SONM). This can be considered as Fairly Valued.


Can you provide the profitability details for DNA X INC?

DNA X INC (SONM) has a profitability rating of 0 / 10.


How financially healthy is DNA X INC?

The financial health rating of DNA X INC (SONM) is 0 / 10.